Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies

Part of paid clinical trials in Indianapolis, Indiana.

Sponsor
Regeneron Pharmaceuticals
Study ID
NCT01688960
Phase
PHASE1
Status
Completed

Conditions

  • Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is an open-label, multicenter, ascending, multiple dose study of nesvacumab (REGN910/ SAR307746) in combination with aflibercept ("ziv-aflibercept" in the U.S.)

Key Dates

Start date
Oct 31, 2012
Status verified
Mar 2015
Primary completion
Nov 30, 2014
Completion
Nov 30, 2014

Study Design

Enrollment
48 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1
  • Experimental: Cohort 2
  • Experimental: Cohort 3a
  • Experimental: Cohort 3b
  • Experimental: Cohort 4

Primary Outcome Measure

Maximum Tolerable Dose (MTD) or Recommended Phase 2 Dose (RP2D) [ Time Frame: Day 1 to Day 28 ]

Locations (5)

FacilityCityStateZIPSite coordinators
-IndianapolisIndiana--
-New YorkNew York--
-Oklahoma CityOklahoma--
-PhiladelphiaPennsylvania--
-San AntonioTexas--

Related Studies